Impact of socio-demographic co-variates on prognosis, tyrosine kinase-inhibitor use and outcomes in persons with newly-diagnosed chronic myeloid leukaemia
- PMID: 33835260
- PMCID: PMC11800769
- DOI: 10.1007/s00432-021-03624-4
Impact of socio-demographic co-variates on prognosis, tyrosine kinase-inhibitor use and outcomes in persons with newly-diagnosed chronic myeloid leukaemia
Abstract
Purpose: Define the impact of socio-demographic co-variates on outcomes of persons with newly-diagnosed chronic phase chronic myeloid leukaemia (CML).
Methods: Data of 961 consecutive subjects with newly-diagnosed CML were integrated for these outcomes in multi-variable Cox regression analyses after adjusting for confounders and interactions.
Results: Elder age was associated with less use of a 2nd generation TKI as initial therapy. Household registration, comorbidity(ies) and education level were associated with use of a generic rather than branded TKI as initial therapy. Subjects with lower education level were more likely to be diagnosed with CML because of leukaemia-related symptoms. Rural registration and lower education level were also associated with a greater likelihood of switching TKI-therapy. Lower education level was associated with lower likelihood of achieving MMR [HR = 0.8 (0.7, 0.9), p = 0.002], MR4.5 [HR = 0.8 (0.7, 1.0), p = 0.055], and poor FFS [HR = 1.7 (1.3, 2.5); p < 0.001], PFS [HR = 2.0 (1.1, 5.0); p = 0.014], CML-related survival [HR = 2.5 (1.0, 10.0); p = 0.060] and survival [HR = 2.5 (1.0, 10.0); p = 0.043]. Males had lower rates of MMR and MR4.5 and worse FFS, but not survival compared with females. Being married was associated with a higher rate of MR4.5, fewer failures, progressions, and deaths.
Conclusion: Socio-demographic co-variates have a strong impact on therapy choice and responses in persons with newly-diagnosed CML, including circumstances of diagnosis, risk category and prognosis, use of initial TKI, switching TKIs, response to TKI-therapy, and outcomes.
Keywords: Chronic; Leukaemia; Myeloid; Socio-demographic co-variates; Tyrosine kinase inhibitor.
© 2021. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.
Conflict of interest statement
RPG is a consultant to BeiGene Ltd., Fusion Pharma LLC, LaJolla NanoMedical Inc., Mingsight Parmaceuticals Inc. and CStone Pharmaceuticals; advisor to Antegene Biotech LLC, Medical Director, FFF Enterprises Inc.; partner, AZAC Inc.; Board of Directors, Russian Foundation for Cancer Research Support; and Scientific Advisory Board: StemRad Ltd.
Figures



Similar articles
-
Variables associated with patient-reported outcomes in persons with chronic myeloid leukemia receiving tyrosine kinase-inhibitor therapy.J Cancer Res Clin Oncol. 2017 Jun;143(6):1013-1022. doi: 10.1007/s00432-017-2353-2. Epub 2017 Mar 1. J Cancer Res Clin Oncol. 2017. PMID: 28251350 Free PMC article.
-
Molecular monitoring of tyrosine kinase inhibitor therapy of chronic myeloid leukemia in China.J Cancer Res Clin Oncol. 2016 Jul;142(7):1549-55. doi: 10.1007/s00432-016-2158-8. Epub 2016 Apr 16. J Cancer Res Clin Oncol. 2016. PMID: 27085530 Free PMC article.
-
Higher out-of-pocket expenses for tyrosine kinase-inhibitor therapy is associated with worse health-related quality-of-life in persons with chronic myeloid leukemia.J Cancer Res Clin Oncol. 2017 Dec;143(12):2619-2630. doi: 10.1007/s00432-017-2517-0. Epub 2017 Sep 11. J Cancer Res Clin Oncol. 2017. PMID: 28894944 Free PMC article.
-
Comparative Effectiveness of Newer Tyrosine Kinase Inhibitors Versus Imatinib in the First-Line Treatment of Chronic-Phase Chronic Myeloid Leukemia Across Risk Groups: A Systematic Review and Meta-Analysis of Eight Randomized Trials.Clin Lymphoma Myeloma Leuk. 2016 Jun;16(6):e85-94. doi: 10.1016/j.clml.2016.03.003. Epub 2016 Mar 30. Clin Lymphoma Myeloma Leuk. 2016. PMID: 27101984
-
Dasatinib, nilotinib and standard-dose imatinib for the first-line treatment of chronic myeloid leukaemia: systematic reviews and economic analyses.Health Technol Assess. 2012;16(42):iii-iv, 1-277. doi: 10.3310/hta16420. Health Technol Assess. 2012. PMID: 23134589
Cited by
-
[Survey and analysis of the concerns of patients with chronic myeloid leukemia in China in 2021].Zhonghua Xue Ye Xue Za Zhi. 2022 Sep 14;43(9):760-765. doi: 10.3760/cma.j.issn.0253-2727.2022.09.008. Zhonghua Xue Ye Xue Za Zhi. 2022. PMID: 36709170 Free PMC article. Chinese.
-
[Combination of socio-demographic and clinical co-variates for predicting treatment responses and outcomes in patients with chronic myeloid leukemia in the chronic phase].Zhonghua Xue Ye Xue Za Zhi. 2022 Jan 14;43(1):54-62. doi: 10.3760/cma.j.issn.0253-2727.2022.01.011. Zhonghua Xue Ye Xue Za Zhi. 2022. PMID: 35231994 Free PMC article. Chinese.
-
A predictive model for therapy failure in patients with chronic myeloid leukemia receiving tyrosine kinase inhibitor therapy.Blood. 2024 Oct 31;144(18):1951-1961. doi: 10.1182/blood.2024024761. Blood. 2024. PMID: 39046786 Free PMC article.
-
[Treatment status of tyrosine kinase inhibitor for newly-diagnosed chronic myeloid leukemia: a domestic multi-centre retrospective real-world study].Zhonghua Xue Ye Xue Za Zhi. 2024 Mar 14;45(3):215-224. doi: 10.3760/cma.j.cn121090-20231108-00255. Zhonghua Xue Ye Xue Za Zhi. 2024. PMID: 38716592 Free PMC article. Chinese.
-
Patient Versus Physician Perspective in the Management of Chronic Myeloid Leukemia During Treatment with Tyrosine Kinase Inhibitors.Oncol Ther. 2024 Mar;12(1):131-145. doi: 10.1007/s40487-023-00255-2. Epub 2023 Dec 16. Oncol Ther. 2024. PMID: 38104036 Free PMC article.
References
-
- Baccarani M, Saglio G, Goldman J, Hochhaus A, Simonsson B, Appelbaum F et al (2006) Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet. Blood 108(6):1809–1820. 10.1182/blood-2006-02-005686 - PubMed
-
- Branford S, Yeung DT, Ross DM, Prime JA, Field CR, Altamura HK et al (2013) Early molecular response and female sex strongly predict stable undetectable BCR-ABL1, the criteria for imatinib discontinuation in patients with CML. Blood 121(19):3818–3824. 10.1182/blood-2012-10-462291 - PubMed
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical